When a patient with a confirmed prior episode of immune-mediated thrombotic thrombocytopenic purpura (iTTP) presents with relapse, clinical management requires a structured, protocol-driven approach that goes beyond watchful waiting. Relapsed iTTP is a distinct and urgent clinical situation.
This protocol addresses immune-mediated TTP (iTTP) in the setting of relapse — defined as a recurrence following a previous documented episode. The relapsing nature of iTTP distinguishes this population from first-presentation patients and drives specific treatment recommendations.
Evidence-based management centers on therapeutic plasma exchange (TPE) combined with immunosuppressive therapy. For relapsing iTTP specifically, current guidelines support augmenting this foundation with additional targeted immunotherapy. The complete agent selection, sequencing, and structured regimen are available in the full protocol.